
Annexin Pharmaceuticals AB
ANNX | ST
Overview
Corporate Details
- ISIN(s):
- SE0009664154
- LEI:
- 5493000JP703HGPJEX27
- Country:
- Sweden
- Address:
- KAMMAKARGATAN 48, 111 60 Stockholm
- Website:
- https://annexinpharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on developing therapies centered on the human protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant form of Annexin A5 designed to target the lipid phosphatidylserine (PS), which is exposed on the surface of stressed and damaged cells. By binding to PS, ANXV aims to create a protective shield that counteracts cellular stress, modulates immune responses, and repairs tissue injury. The company is primarily investigating ANXV's therapeutic potential in ophthalmology, specifically for Retinal Vein Occlusion (RVO), where it is positioned as a potential First-in-Class treatment, and in oncology. The drug's unique mechanism of action offers a novel approach for various diseases where PS exposure is a contributing factor.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Annexin Pharmaceuticals AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
No filings match the current criteria. |
Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |